These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1243 related items for PubMed ID: 17065392

  • 1. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [Abstract] [Full Text] [Related]

  • 2. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [Abstract] [Full Text] [Related]

  • 3. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
    Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP.
    Arch Biochem Biophys; 2004 Aug 15; 428(2):136-43. PubMed ID: 15246869
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 15; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 5. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug 15; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
    Irwin N, McClean PL, Cassidy RS, O'harte FP, Green BD, Gault VA, Harriott P, Flatt PR.
    Diabetes Metab Res Rev; 2007 Oct 15; 23(7):572-9. PubMed ID: 17315241
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
    Irwin N, Gault VA, Green BD, Greer B, McCluskey JT, Harriott P, O'Harte FP, Flatt PR.
    Biol Chem; 2004 Sep 15; 385(9):845-52. PubMed ID: 15493880
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA, Kerr BD, Harriott P, Flatt PR.
    Clin Sci (Lond); 2011 Aug 15; 121(3):107-17. PubMed ID: 21332446
    [Abstract] [Full Text] [Related]

  • 16. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X, Harada N, Yamane S, Kitajima L, Uchida S, Hamasaki A, Mukai E, Toyoda K, Yamada C, Yamada Y, Seino Y, Inagaki N.
    Life Sci; 2009 Jun 19; 84(25-26):876-81. PubMed ID: 19358859
    [Abstract] [Full Text] [Related]

  • 17. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jun 19; 88(6):2706-13. PubMed ID: 12788877
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chronic exposure to incretin metabolites GLP-1(9-36) and GIP(3-42) affect islet morphology and beta cell health in high fat fed mice.
    Sridhar A, Khan D, Babu G, Irwin N, Gault VA, Flatt PR, Moffett CR.
    Peptides; 2024 Aug 19; 178():171254. PubMed ID: 38815655
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.